快要 飞的 《药股》 讨论区

葉芬

原帖由 m.i.k.e 于 27-11-2009 09:33 AM 发表
最近,正计划年尾离家出走,去看山看海, 所以没闲钱招持你.

杜拜泡沫破了。。

嘩 還有心情游山玩水？

miku

去dubai玩咯。。

葉芬

原帖由 miku 于 27-11-2009 03:21 PM 发表
去dubai玩咯。。

Not a bad idea ...  

葉芬

沒法子，這樣的行情，
CVM 會先賣後買回。

miku

我等avii跌破1.4.。。大举买入

miku

napster 来改一下帖名又闭关去了

葉芬

Date        Open        High        Low        Last        Change        Volume        % Change
11/27/09        1.18        1.31        1.14        1.29        +0.08        3848294        +6.61%

Composite Indicator       
   Trend Spotter TM                Sell

Short Term Indicators       
   7 Day Average Directional Indicator                Sell
   10 - 8 Day Moving Average Hilo Channel                Hold       
   20 Day Moving Average vs Price        Buy       
   20 - 50 Day MACD Oscillator                Sell
   20 Day Bollinger Bands                Hold       

Short Term Indicators Average:          20% - Sell
20-Day Average Volume - 5406110

Medium Term Indicators       
   40 Day Commodity Channel Index                Hold       
   50 Day Moving Average vs Price                Sell
   20 - 100 Day MACD Oscillator        Buy       
   50 Day Parabolic Time/Price        Buy       

Medium Term Indicators Average:          25% - Buy
50-Day Average Volume - 10308021

Long Term Indicators       
   60 Day Commodity Channel Index                Hold       
   100 Day Moving Average vs Price        Buy       
   50 - 100 Day MACD Oscillator        Buy       

Long Term Indicators Average:          67% - Buy
100-Day Average Volume - 8728693

Overall Average:          8% - Buy

Price         Support         Pivot Point         Resistance
1.29         1.08         1.25         1.42

葉芬

1/12/09


Somaxon Pharmaceuticals, Inc. (SOMX) - SOMX exploded on Monday as traders appear to be buying ahead of the FDA decision due out early next week. There is strong resistance between $4.78-$5.00.

葉芬

YMZ09.CBT        Mini Dow Jones Indus.-$5 Dec 09        10,404.00  5:53am ET        Up 70.00 (0.68%)

葉芬

Good News................



*CEL-SCI Corp. Retains Services Of International Contract Research Organization To Manage Upcoming Phase III Clinical T

葉芬

CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug M

CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for
Its Cancer Drug Multikine

Tue Dec 01 10:15:00 2009
EST
VIENNA, Va., Dec 01, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --
CEL-SCI Corporation (NYSE Amex: CVM), a late-stage oncology company and a developer
of vaccines and therapeutics for the prevention and treatment of infectious diseases,
announced today that it has retained the services of an international Contract Research
Organization (CRO) to run CEL-SCI's upcoming Phase III clinical trial in advanced
primary head and neck cancer with the Company's lead product candidate, Multikine(R).
This CRO is considered to be one of the world's top CRO's for running global oncology
studies.
The impending Phase III trial is expected to enroll up to 800 patients with
advanced primary head and neck cancer in multiple countries around the world.  It
will evaluate Multikine's ability to increase the overall survival of treated patients
when used in conjunction with the current standard of care treatment.
"We are very pleased to have retained the services of a well respected and
internationally recognized CRO which specializes in conducting late-stage oncology
trials to guide our pivotal Phase III trial for Multikine," said Geert Kersten,
Chief Executive Officer of CEL-SCI.  "After carefully evaluating many competing
organizations, we have chosen this CRO based on their extensive experience in managing
global clinical trials of medicines ultimately approved for the treatment of cancer."
In Phase II clinical trials Multikine was shown to be safe and well-tolerated,
and to improve patients' overall survival by 33% at a median of three and a half
years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead
for a Phase III clinical trial and granted orphan drug status to Multikine in the
neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck. CEL-SCI
recently took delivery of its new state of the art manufacturing facility which
will produce Multikine for the upcoming Phase III trial.
About Multikine
Multikine, a patented defined mixture of naturally derived cytokines, is
the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS".
Immune SIMULATORS simulate the way our natural immune system acts in defending us
against cancer. As opposed to other immunotherapies which are designed to target
a single or limited number of specific antigens or molecules, Immune SIMULATORS
are multi-targeted; they simultaneously cause a direct and targeted killing of the
specific tumor cells and they activate the immune system to produce a stronger anti-tumor
attack on multiple fronts.
Multikine is also the first immunotherapeutic agent being developed as a
first-line standard of care treatment for cancer. It is administered prior to any
other cancer therapy because that is the period when the anti-tumor immune response
can still be fully activated. Once the patient has advanced disease, or had surgery
or has received radiation and/or chemotherapy, the immune system is severely weakened
and is less able to mount an effective anti-tumor immune response. Other immunotherapies
are administered after the patient has received chemotherapy and/or radiation therapy,
which can limit their effectiveness.
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses.
Its lead product is Multikine which is being readied for a global Phase III trial
in advanced primary head and neck cancer. CEL-SCI is also developing a vaccine to
treat H1N1 hospitalized patients using its L.E.A.P.S.(TM) technology platform.  
This investigational treatment involves non-changing regions of H1N1 Pandemic Flu,
Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about
the creation of a new more virulent hybrid virus through the combination of H1N1
and Avian Flu, or maybe Spanish Flu.  The Company has operations in Vienna, Virginia,
and Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
When used in this report, the words "intends," "believes," "anticipated"
and "expects" and similar expressions are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties which could cause actual
results to differ materially from those projected. Factors that could cause or contribute
to such differences include, an inability to duplicate the clinical results demonstrated
in clinical studies, timely development of any potential products that can be shown
to be safe and effective, receiving necessary regulatory approvals, difficulties
in manufacturing any of the Company's potential products, inability to raise the
necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's
SEC filings, including but not limited to its report on Form 10- K/A for the year
ended September 30, 2008. The Company undertakes no obligation to publicly release
the result of any revision to these forward-looking statements which may be made
to reflect the events or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
SOURCE  CEL-SCI Corporation
http://www.cel-sci.com
Copyright (C) 2009 PR Newswire. All rights reserved

CVM,

CEL-SCI-cancer-trial, BUSINESS, csta+stories, FINANCE, financenews, financenews+select, HEALTHCARE, hedge+funds,
PHARMACEUTICALS, prn, PUBCO+SELECT, PUBLIC+COMPANIES, WALL+STREET,

葉芬

奇怪 CVM 好消息出，股價還是停留在那。。。
看來要等到一 “梗” 的好好消息才會飛了。。。

m.i.k.e

Dyax Corp.(NasdaqGM: DYAX)
After Hours: 5.10  1.60 (45.71%) 7:59pm ET

http://www.businesswire.com/news/home/20091201006541/en

Dyax Announces FDA Approval of KALBITOR® (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema in Patients 16 Years of Age and Older

葉芬

原帖由 m.i.k.e 于 2-12-2009 11:03 AM 发表
Dyax Corp.(NasdaqGM: DYAX)
After Hours: 5.10  1.60 (45.71%) 7:59pm ET

http://www.businesswire.com/news/home/20091201006541/en

Dyax Announces FDA Approval of KALBITOR® (ecallantide) for the  ...

麥麥，你有進到貨嗎？

m.i.k.e

原帖由 葉芬 于 2-12-2009 11:04 AM 发表




麥麥，你有進到貨嗎？

没有.

最近运气不好,所以减少动作,但有密切注意他.

葉芬

原帖由 m.i.k.e 于 2-12-2009 11:14 AM 发表
没有.

最近运气不好,所以减少动作,但有密切注意他.

有注意沒買嗎？
買1粒也可以嘛。


我看目前我還是乖乖的專注 MPEL 吧。
小的金融股對我無緣。
一買股價就跌！

m.i.k.e

原帖由 葉芬 于 2-12-2009 11:18 AM 发表



有注意沒買嗎？
買1粒也可以嘛。


我看目前我還是乖乖的專注 MPEL 吧。
小的金融股對我無緣。
一買股價就跌！

小的金融股不是不能买,只是风险高,而且个人认为只适合做短线,或不带过夜最好.

我现在没有看美市到通宵了,所以也没有做  day trade.

m.i.k.e

另外一只错过了的药股........
以为会在星期五才公布....

Santarus, Inc.(NasdaqGM: SNTS)
After Hours: 5.80  1.51 (35.20%) 7:59pm ET

http://www.businesswire.com/port ... 508&newsLang=en

Santarus Announces FDA Approval of Schering-Plough HealthCare Products’ ZEGERID OTC

m.i.k.e

一些将会有诮息/成绩公布的医药股 : SOMX, INHX, ENDP, GENT, PSDV, SLXP, CEPH

葉芬

原帖由 m.i.k.e 于 2-12-2009 11:51 AM 发表
一些将会有诮息/成绩公布的医药股 : SOMX, INHX, ENDP, GENT, PSDV, SLXP, CEPH

謝謝分享。。